Asset / Drug

Oncology

Drug and asset intelligence for Oncology with 34 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 34
Catalysts: 0
Stage: Development stage unavailable

Sponsor company

Roche →

Mechanism of action

PD-1 Inhibitor

Recent signals(34)

CompetitiveJune 18, 2026

First-in-human study of NTSR1-targeted imaging in prostate cancer shows promise

[18F]-AlF-NOTA-neurotensin shows potential as an NTSR1-targeted radiotracer for prostate cancer imaging.

ClinicalJune 18, 2026

St. Jude's Protocol for Long-term Review of Childhood Cancer Survivors

Jude Children's Research Hospital is implementing a protocol to monitor outcomes and late toxicity in childhood cancer patients.

ClinicalJune 18, 2026

Study on Frailty in Young Adult Survivors of Childhood Cancer Highlights Long-term Health Risks

A longitudinal study assesses frailty in young adult survivors of childhood cancer, revealing significant health risks.

RegulatoryJune 18, 2026

FDA Grants Priority Review for KEYTRUDA QLEX Supplement Application

The FDA has granted priority review for the supplemental application of KEYTRUDA QLEX, which includes pembrolizumab and berahyaluronidase alfa-PMPH.

StrategyJune 18, 2026

Alembic submits ANDA for Bosutinib Monohydrate

Alembic has submitted an Abbreviated New Drug Application (ANDA) for Bosutinib Monohydrate.

ClinicalJune 18, 2026

Phase II Trial of Proton Therapy for Craniopharyngioma Shows Feasibility and Safety

A Phase II trial is assessing the feasibility and safety of combining limited surgery with proton therapy for craniopharyngioma.

ClinicalJune 18, 2026

Study on De-escalation of Radiation Therapy in Node Negative Breast Cancer

A clinical trial is investigating the de-escalation of radiation therapy in women with clinically node negative breast cancer undergoing lumpectomy.

ClinicalJune 18, 2026

Study on ACS Geriatric Surgery Program's Impact on Older Cancer Patients

The study evaluates the implementation of the ACS GSV Program at James Cancer Hospital to enhance surgical outcomes for older adults.

ClinicalJune 18, 2026

Feasibility Study on Sensory Changes in Pediatric Oncology Patients Undergoing Treatment

The CANUT Junior study is assessing sensory changes in pediatric oncology patients, with initial recruitment challenges leading to protocol amendments.

ClinicalJune 17, 2026

ROBIN Trial to Explore RT Effects on Immune System in Rectal Cancer

The ROBIN trial will investigate the molecular effects of standard short course radiotherapy on rectal cancer and its impact on the immune system.

ClinicalJune 17, 2026

Zilovertamab Vedotin Shows Promise in rrDLBCL with Standard Care in Phase 2/3 Study

A Phase 2/3 study is evaluating zilovertamab vedotin in combination with standard care for rrDLBCL, with a protocol amendment discontinuing enrollment in one cohort.

ClinicalJune 17, 2026

Study on Exercise Program's Impact on Quality of Life in Prostate Cancer Patients

A clinical trial is assessing the effects of a structured exercise program on quality of life and health outcomes in prostate cancer patients.

ClinicalJune 17, 2026

Phase 2 Study of AUR103 Calcium in Advanced Neuroendocrine Tumours Initiated

AUR103 calcium is being evaluated in Phase 2 study for efficacy and safety in advanced neuroendocrine tumors.

ClinicalJune 17, 2026

E7 mRNA/LNP vaccine shows promise in treating early-stage HPV tumors in mice

The study demonstrates that the HPV16 E7 mRNA/LNP vaccine induces strong immune responses and tumor regression in early-stage HPV tumors in mice.

RegulatoryJune 17, 2026

Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma

Tebentafusp (IMCgp100) significantly improved overall survival in HLA-A*02:01-positive advanced uveal melanoma, establishing it as a first-line treatment.

ClinicalJune 17, 2026

Study on Socio-aesthetics Care Impact on Cancer Patients' Quality of Life

A randomized controlled trial is evaluating the impact of socio-aesthetics well-being care on quality of life, pain, and anxiety in cancer patients.

RegulatoryJune 17, 2026

Ifinatamab Deruxtecan Receives Priority Review for ES-SCLC in the U.S.

Ifinatamab deruxtecan's Biologics License Application has been accepted and granted Priority Review by the FDA for ES-SCLC.

ClinicalJune 17, 2026

Trial Evaluates Pelvic Radiotherapy with ADT in Node Positive Prostate Cancer

A clinical trial is assessing the efficacy of adding pelvic radiotherapy to androgen deprivation therapy in patients with node-positive prostate cancer post-prostatectomy.

ClinicalJune 17, 2026

Phase III Trial Evaluates Hormone Therapy and Chemotherapy in Invasive Breast Cancer

A randomized phase III trial is assessing the efficacy of tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy in invasive breast cancer.

RegulatoryJune 16, 2026

FDA ODAC Vote Against Camizestrant for HR-Positive Breast Cancer Raises Concerns

The FDA's ODAC did not reach a majority vote in favor of camizestrant's benefit-risk profile for advanced HR-positive breast cancer.

StrategyJune 16, 2026

Merck Acknowledges Daiichi Sankyo's ADC Manufacturing Update

Merck has acknowledged Daiichi Sankyo's update regarding its manufacturing and supply plan for ADC products.

CompetitiveJune 16, 2026

Roche to Acquire PathAI for $750M to Enhance AI-Driven Diagnostics

Roche has entered into a definitive agreement to acquire PathAI for $750 million, enhancing its digital pathology capabilities.

StrategyJune 16, 2026

Roche to Acquire PathAI for $750M to Enhance AI-Driven Diagnostics

Roche has entered into a definitive merger agreement to acquire PathAI for $750 million, enhancing its digital pathology capabilities.

RegulatoryJune 16, 2026

FDA Extends Decision Date for AstraZeneca's Camizestrant in HR-positive Breast Cancer

The FDA has extended the PDUFA date for camizestrant to allow for additional data review related to its NDA.

ClinicalJune 16, 2026

Merck's Sacituzumab Tirumotecan Shows OS and PFS Improvement in Endometrial Cancer Phase 3 Trial

The TroFuse-005 trial demonstrated that sacituzumab tirumotecan significantly improved overall survival and progression-free survival compared to chemotherapy in patients with advanced or recurrent endometrial cancer.

StrategyJune 16, 2026

Roche and Nurix Collaborate on BTK Degrader Bexobrutideg for B-cell Malignancies

Roche has entered a collaboration with Nurix Therapeutics to co-develop bexobrutideg, BTK degrader targeting B-cell malignancies, immunology, and neurology.

CompetitiveJune 16, 2026

Pfizer and Innovent Collaborate on 12 Early-Stage Oncology Programs

Pfizer and Innovent Biologics have entered a strategic collaboration to co-develop 12 early-stage cancer medicines, including antibody-drug conjugates.

ClinicalJune 16, 2026

Roche to Present Promising Giredestrant Data at ASCO 2026 for Early Breast Cancer

Roche will present new data from the lidERA and persevERA studies, indicating giredestrant's potential as a new standard of care in early and advanced ER-positive breast cancer.

ClinicalJune 16, 2026

Roche to Present Promising Giredestrant Data at ASCO 2026 for Early Breast Cancer

Roche will present new data from the lidERA and persevERA studies, highlighting giredestrant's potential as a new standard of care for ER-positive breast cancer.

RegulatoryJune 16, 2026

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer

The FDA has accepted Roche's NDA for giredestrant, an oral SERD, under priority review based on phase III data showing a 30% reduction in invasive disease recurrence or death compared to standard therapy.

RegulatoryJune 16, 2026

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer

The FDA has accepted Roche's NDA for giredestrant, showing a 30% reduction in invasive disease recurrence compared to standard therapy.

ClinicalJune 2, 2026

Imfinzi+Imjudo shows significant PFS improvement in early liver cancer trial

The EMERALD-3 Phase III trial demonstrated a statistically significant improvement in progression-free survival for Imfinzi plus Imjudo in patients with unresectable liver cancer.

ClinicalJune 2, 2026